Skip to main content

Table 3 Safety outcome reporting of gout flare prophylaxis and therapy use with renal function stratification

From: Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review

First Author (Year)
(Trial Name)
Adverse/Serious Adverse Events Reported by Renal Function Notable Findings
COLCHICINE
AKDAG 2006 [17] Yes Colchicine toxicity in the context of antibiotic use (clarithromycin and cefepime) for pneumonia. Besides worsening renal function, there was associated mild pancytopaenia and liver impairment.
ALAYLI 2005 [18] Yes Colchicine neuromyopathy in the context of concomitant statin use.
ALTMAN 2007 [20] Yes Colchicine-induced rhabdomyolysis.
BONNEL 2002 [22] Yes Fatal colchicine toxicity with rapidly deteriorating renal function and death.
BOUQUIÉ 2011 [24] Yes Colchicine-induced rhabdomyolysis with acute decompensation of pre-existing double heart/lung transplant and multi-organ failure.
ELEFTHERIOU 2008 [28] Yes Colchicine toxicity with multi-organ failure in the context of concomitant long-term cyclosporin therapy for heart transplant.
GARROUSTE 2012 [29] Yes Colchicine toxicity with neuromyopathy and multi-organ failure in the context of concomitant long-term cyclosporin use for renal transplant.
HUH 2013 [31] Yes Colchicine toxicity with gastrointestinal symptoms and neuromyopathy in the context of concomitant long-term cyclosporin use for renal transplant and statin use.
JUSTINIANO 2007 [32] Yes Colchicine-induced rhabdomyolysis in the context of concomitant statin use.
KUBLER 2000 [33] Yes Fatal colchicine toxicity with multi-organ failure and death.
LAI 2006 [35] Yes Colchicine neuromyopathy.
LEE 1997 [36] Yes Acute myopathy in the context of concomitant cyclosporin use for renal transplant.
LY 2007 [37] Yes One patient with CKD (serum creatinine of 0.21 mmol/L) developed colchicine myopathy.
MEDANI 2016 [39] Yes Colchicine neuromyopathy.
NEUSS 1986 [44] Yes Fatal colchicine toxicity with myopathy, multi-organ failure, severe neutropaenia with associated disseminated candidiasis and death.
PATEL 2016 [46] Yes Colchicine-induced rhabdomyolysis in the context of statin use and initiation of sofosbuvir/ledipasvir therapy for Hepatitis C.
RIEGER 1990 [49] Yes Colchicine neuromyopathy in the context of acute stage of post-renal transplant and cyclosporin use.
WILBUR 2004 [53] Yes Colchicine neuromyopathy.
YOON 2001 [55] Yes Colchicine toxicity with associated pancytopaenia, neuromyopathy and total alopecia.
ZAGLER 2009 [57] Yes Colonic perforation and acute on chronic CKD.
IL-1 INHIBITORS
ADLER 2007 [67] No Anakinra treatment: adverse event was not reported.
AOUBA 2015 [68] Yes Anakinra treatment: 1 patient with mild injection site reaction, transient diffuse pruritus and episodic diarrhoea.
BARTOV 2013 [69] Yes Anakinra treatment: adverse event was not observed.
DIREZ 2012 [71] Yes Anakinra treatment: non-complicated neutropaenia.
LOUSTAU 2018 [76] Yes Anakinra treatment: 1 patient with an infection (nosocomial pyelonephritis). No other adverse event was observed.
MAROTTO 2018 [77] Yes Canakinumab treatment: adverse event was not observed.
PEREZ-RUIZ 2013 [81] Yes Anakinra treatment: 1 patient with recurrent heart failure. No other adverse event was observed.
TRAN 2011 [83] Yes Anakinra treatment: adverse event was not reported.
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
KAHL 1989 [84] Yes Acute kidney injury with sulindac and indomethacin use.
SCHLONDORFF 1993 [86] Yes Acute kidney injury with indomethacin use.
ZAGLER 2009 [57] Yes Colonic perforation and acute on chronic CKD.
GLUCOCORTICOIDS
TAUSCHE 2011 [95] No Adverse event was not reported.
ZAGLER 2009 [57] Yes Colonic perforation and acute on chronic CKD.
  1. CKD Chronic kidney disease